Alfredo Addeo, Head of Oncology Department at Geneva University Hospitals, shared a post on X:
“Breaking: The Phase 3 DeLLphi-304 trial met its primary endpoint: Imdelltra (tarlatamab-dlle) significantly improved overall survival vs SOC in SCLC patients post-platinum. A major step forward for this hard-to-treat disease. Look forward to seeing the data.”
